AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02346786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: eau minérale d'Aix-Les-Bains
Description: Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
Study NCT02346786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tap water
Study NCT04874142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYC506-T
Description: single administration
Study NCT04874142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYC506-A
Description: single administration
Study NCT04874142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYC506-T + YYC506-A
Description: concomotant administration
Study NCT04874142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYC506-A + YYC506-T
Description: concomotant administration
Study NCT01714908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erlotinib w Concurrent Radiotherapy
Study NCT01714908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: etoposide/cis-platin (EP) w Concurrent Radiotherapy
Description: Etoposide / Cis-platin w Concurrent Radiotherapy
Study NCT02064686 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Exhaled breath temperature
Study NCT00567606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength/Weight Training & Drug/Supplement
Description: G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
Study NCT00567606 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug/Supplement only
Description: G2 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week, but do not participate in strength/weight training exercises.
Study NCT03607851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide - conventional titration
Description: Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
Study NCT03607851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide - rapid titration 1
Description: Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
Study NCT03607851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide - rapid titration 2
Description: Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
Study NCT03052517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039 150 mg
Description: One tablet of QAW039 150 mg once daily
Study NCT03052517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039 450 mg
Description: One tablet of QAW039 450 mg once daily
Study NCT00775333 — intervention group
Intervention type: PROCEDURE
Intervention: Outcome after carpal tunnel release
Description: Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
Study NCT03052517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of Placebo once daily
Study NCT01401712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ON-Q® Pain Relief System
Description: Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
Study NCT01401712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter
Description: Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
Study NCT03369613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial electrical stimulation
Description: The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
Study NCT03369613 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial electrical stimulation
Description: The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
Study NCT01612897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer based care reminders
Description: Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
Study NCT03201159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX103
Description: 150mg tablets
Study NCT06423560 — intervention group
Intervention type: RADIATION
Intervention: Computed tomography
Description: Follow-up computed tomography at 3-6 months and 12 months
Study NCT03549637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Psychiatric population
Description: Genetic and biological analysis of patients
Study NCT02347124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
Study NCT02347124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
Study NCT00482209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone, misoprostol
Description: 200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
Study NCT00482209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifepristone, misoprostol
Description: 200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
Study NCT03965234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given via infusion
Study NCT03965234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated Chemotherapeutic Lung Perfusion
Description: Undergo pulmonary suffusion
Study NCT01424228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
Study NCT01424228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: Prucalopride 2 mg daily before breakfast~1 mg for subjects >65 years; in case of insufficient response 2 mg at week 2 or week 4
Study NCT00509171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reamer Irrigator Aspirator
Description: Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
Study NCT04135846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: 16 mg or maximum tolerated dose (MTD)
Study NCT04135846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT04588090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The concurrent 3 weeks TP regimen
Description: paclitaxel + cisplatin regimen (TP-TAX: 150mg/m\^2, DDP: 70mg/m\^2 (35mg/m\^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
Study NCT04588090 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The concurrent weekly TP regimen
Description: paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m\^2, DDP: 25mg/m\^2) 6 cycles of chemotherapy
Study NCT04588090 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiation plus intraluminal after-loading irradiation
Description: External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
Study NCT04588090 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External radiation plus intraluminal after-loading irradiation
Description: External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
Study NCT04734587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood serum Neuron-specific Enolase measurement
Description: The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
Study NCT04054466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART
Description: It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly.
Study NCT04054466 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Habitual Counseling
Description: Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
Study NCT02879578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Study NCT00865839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl 500 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study NCT00865839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOPHAGE® XR 500 mg tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study NCT01426776 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: heart valve replacement
Description: The patients with heart valve disease and CSR will be received heart valve replacement
Study NCT01288547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: theobromine
Description: 700 mg theobromine in gelatin capsules given one time only
Study NCT01288547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 120 mg caffeine in capsules given one time only
Study NCT01288547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: caffeine + theobromine
Description: 120 mg caffeine and 700 mg theobromine in capsules given one time only
Study NCT01288547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cellulose in capsules given one time only
Study NCT03645109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
Study NCT03645109 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsules with placebo (talcum food grade)
Description: Capsules with placebo (talcum food grade)
Study NCT03965234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy
Study NCT01876056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CaCBTp
Description: Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
Study NCT01492660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: echogenic needle and catheter
Description: Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
Study NCT01492660 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation to position needle and catheter
Description: The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
Study NCT02424708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Glutathione 100mg
Description: 100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
Study NCT02424708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Glutathione 200mg
Description: 200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
Study NCT02424708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
Study NCT00002625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00002625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy
Study NCT00002625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT01927276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten Free Flour
Study NCT02586155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: High-Intensity Statin
Study NCT02586155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: High-Intensity Statin
Study NCT02586155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: High-Intensity Statin
Study NCT02234076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRET
Study NCT02369328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MULTIMODAL MRI
Description: Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
Study NCT02369328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MULTIMODAL MRI
Description: Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
Study NCT02234076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as usual offered by the participating mental health care organisations
Study NCT01958138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison of group-I (low dose propofol with isoflurane)
Description: Prior to LMA removal in group-I, isoflurane MAC awake (MAC less than 0.5) will be achieved in expiratory gases with 60% nitrous oxide and 40% oxygen. Propofol 1 mg/Kg will be combined with Isoflurane MAC awake and LMA will be removed after 20 seconds of propofol administration in group-I. The group-II LMA will be removed at end expiratory isoflurane MAC of 1.2% with 60% nitrous oxide and 40% oxygen
Study NCT01927276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat Flour
Study NCT01958138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: comparison of group-I (low dose propofol with isoflurane)
Description: Prior to LMA removal in group-I, isoflurane MAC awake (MAC less than 0.5) will be achieved in expiratory gases with 60% nitrous oxide and 40% oxygen. Propofol 1 mg/Kg will be combined with Isoflurane MAC awake and LMA will be removed after 20 seconds of propofol administration in group-I. The group-II LMA will be removed at end expiratory isoflurane MAC of 1.2% with 60% nitrous oxide and 40% oxygen
Study NCT01159561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Western Equine Encephalitis Vaccine
Description: Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
Study NCT04118023 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 7 Tesla Magnetic Resonance Imaging Test
Description: MAGNETOM Terra - 7T MRI Scanner by Siemens Healthineers. Each patient enrolled will undergo the study imaging test prior to planned diagnostic knee arthroscopy.
Study NCT00378573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00378573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study NCT00378573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00247962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: 50 mg
Study NCT00247962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphasalazine (SSZ)
Description: Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
Study NCT02006602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (GW615775, Test formulation)
Description: Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
Study NCT01527643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
Study NCT02963194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT04150965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab, pomalidomide, dexamethasone
Description: Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
Study NCT04150965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-LAG-3
Description: Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long.
Study NCT04150965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-LAG-3 + Pomalidimide + Dexamethasone
Description: Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
Study NCT02963194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01048736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: 4 d/wk of aerobic exercise
Study NCT01048736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Diet
Description: Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; \~4.5 kg weight loss).
Study NCT02006602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Reference treatment)
Description: Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).